Amicus Therapeutics (FOLD) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $263.9 million.
- Amicus Therapeutics' Cash & Current Investments rose 565.87% to $263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.9 million, marking a year-over-year increase of 565.87%. This contributed to the annual value of $249.9 million for FY2024, which is 1266.74% down from last year.
- Per Amicus Therapeutics' latest filing, its Cash & Current Investments stood at $263.9 million for Q3 2025, which was up 565.87% from $231.0 million recorded in Q2 2025.
- Amicus Therapeutics' Cash & Current Investments' 5-year high stood at $557.0 million during Q3 2021, with a 5-year trough of $231.0 million in Q2 2025.
- Moreover, its 5-year median value for Cash & Current Investments was $280.3 million (2023), whereas its average is $322.7 million.
- As far as peak fluctuations go, Amicus Therapeutics' Cash & Current Investments surged by 2373.4% in 2021, and later plummeted by 3915.08% in 2022.
- Quarter analysis of 5 years shows Amicus Therapeutics' Cash & Current Investments stood at $482.5 million in 2021, then plummeted by 39.15% to $293.6 million in 2022, then fell by 2.52% to $286.2 million in 2023, then dropped by 12.67% to $249.9 million in 2024, then rose by 5.58% to $263.9 million in 2025.
- Its Cash & Current Investments was $263.9 million in Q3 2025, compared to $231.0 million in Q2 2025 and $250.6 million in Q1 2025.